Vanda Pharmaceuticals Inc. (VNDA)

13.21
0.29 2.20
NASDAQ : Health Technology
Prev Close 13.50
Open 13.49
Day Low/High 13.17 / 13.62
52 Wk Low/High 11.83 / 33.44
Volume 1.03M
Avg Volume 729.90K
Exchange NASDAQ
Shares Outstanding 53.27M
Market Cap 702.68M
EPS 0.50
P/E Ratio 24.89
Div & Yield N.A. (N.A)

Latest News

First Week Of VNDA October 18th Options Trading

First Week Of VNDA October 18th Options Trading

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

Vanda Pharmaceuticals FDA Update For HETLIOZ® In The Treatment Of Jet Lag Disorder

Vanda Pharmaceuticals FDA Update For HETLIOZ® In The Treatment Of Jet Lag Disorder

WASHINGTON, Aug. 19, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results

- Q2 2019 Total net product sales of $59.1 million, a 25% increase year over year

First Week Of March 2020 Options Trading For Vanda Pharmaceuticals (VNDA)

First Week Of March 2020 Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the March 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Vanda Pharmaceuticals To Announce Second Quarter 2019 Financial Results On July 31, 2019

Vanda Pharmaceuticals To Announce Second Quarter 2019 Financial Results On July 31, 2019

Conference Call and Webcast to Follow

Vanda Pharmaceuticals FDA Update For HETLIOZ® In The Treatment Of Jet Lag Disorder

Vanda Pharmaceuticals FDA Update For HETLIOZ® In The Treatment Of Jet Lag Disorder

WASHINGTON, July 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on July 19, 2019, it received a notification from the U.

Tradipitant Effective In Preventing Motion Sickness

Tradipitant Effective In Preventing Motion Sickness

WASHINGTON, July 16, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean.

First Week Of VNDA August 16th Options Trading

First Week Of VNDA August 16th Options Trading

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Vanda Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

Vanda Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

WASHINGTON, June 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 19, 2019 at 2:00...

Vanda Pharmaceuticals Announces Participation At The Jefferies 2019 Global Healthcare Conference

Vanda Pharmaceuticals Announces Participation At The Jefferies 2019 Global Healthcare Conference

WASHINGTON, May 31, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that Mihael H.

Tradipitant In The Treatment Of Gastroparesis: Vanda Presents Clinical Trial Results At DDW 2019

Tradipitant In The Treatment Of Gastroparesis: Vanda Presents Clinical Trial Results At DDW 2019

WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week ® (DDW) 2019 in San Diego, CA.

Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results

Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results

- Total net product sales of $47.7 million in the first quarter of 2019, a 9% increase year over year

Vanda Pharmaceuticals Appoints Phaedra Chrousos To Board Of Directors

Vanda Pharmaceuticals Appoints Phaedra Chrousos To Board Of Directors

WASHINGTON, April 24, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that Phaedra Chrousos has joined Vanda's Board of Directors, effective April 23, 2019.

Vanda Pharmaceuticals To Announce First Quarter 2019 Financial Results On May 1, 2019

Vanda Pharmaceuticals To Announce First Quarter 2019 Financial Results On May 1, 2019

Conference Call and Webcast to Follow

Vanda Pharmaceuticals Becomes Oversold (VNDA)

Vanda Pharmaceuticals Becomes Oversold (VNDA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, April 10, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc.

Hagens Berman Reminds Vanda Pharmaceuticals (VNDA) Investors Of April 26, 2019 Lead Plaintiff Deadline And Encourages Investors To Contact The Firm

Hagens Berman Reminds Vanda Pharmaceuticals (VNDA) Investors Of April 26, 2019 Lead Plaintiff Deadline And Encourages Investors To Contact The Firm

SAN FRANCISCO, April 3, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Vanda Pharmaceuticals Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc.

First Week Of May 17th Options Trading For Vanda Pharmaceuticals (VNDA)

First Week Of May 17th Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Relative Strength Alert For Vanda Pharmaceuticals

Relative Strength Alert For Vanda Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

VNDA INVESTOR ALERT: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors Of Important Deadline In First-Filed Case - VNDA

VNDA INVESTOR ALERT: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors Of Important Deadline In First-Filed Case - VNDA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces The Filing Of A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces The Filing Of A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Vanda Pharmaceuticals Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Vanda Pharmaceuticals Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Vanda Pharmaceuticals Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Vanda Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Vanda Pharmaceuticals, Inc.

Federman & Sherwood announces that on February 25, 2019, a class action lawsuit was filed in the United States District Court for the Eastern District of New York against Vanda Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Vanda Pharmaceuticals Inc.

TheStreet Quant Rating: C (Hold)